Daniel Morgensztern, MD, professor, medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine; medical oncologist, Siteman Cancer Center, discusses ongoing research with amivantamab-vmjw (Rybrevant) in non–small cell lung cancer (NSCLC).

Amivantamab, a bispecific antibody that targets EGFR and MET, was approved by the FDA in May 2021 for patients with 

 exon 20 insertions, Morgensztern says. This approval has also led to the initiation of the phase 3 PAPILLON study (NCT04538664), which is looking at chemotherapy with or without amivantamab in patients with 

 exon 20 insertions, Morgensztern explains.

 mutations, amivantamab is also being combined with lazertinib (Leclaza), a third-generation TKI, Morgensztern notes. Encouraging frontline data in this population includes findings from the phase 1 CHRYSALIS trial (NCT02609776). Now, the combination is under study in the phase 3 MARIPOSA trial (NCT04487080), which is looking at first-line amivantamab plus lazertinib vs single-agent lazertinib and osimertinib (Tagrisso) in locally advanced or metastatic NSCLC, Morgensztern concludes.

Videos

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw  in non–small cell lung cancer.

Dr. Morgensztern on Advances With Amivantamab in NSCLC

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non—small cell lung cancer (NSCLC).

Years ago, researchers would not have dreamed that such a treatment would be available for these patients, Morgensztern explains. Immunotherapy started to become a hard focus in 2012, when the first clinical trial was published. At that point, it was unknown how long the responses to treatment would last, but there was little toxicity and interesting activity observed.

When the 5-year follow-up with nivolumab (Opdivo) monotherapy was published in 2015, which had a 3-year survival at 27% with the 3 mg/kg dose, the community knew this would be a significant treatment in the landscape—though, it required some improvements, he adds.

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non–small cell lung cancer (NSCLC).

Daniel Morgensztern, MD

Articles

Dr. Morgensztern on Advances With Amivantamab in NSCLC

Dr. Morgensztern on Impact of Immunotherapy on NSCLC Field